Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity

Medical Hypotheses

Volumn 95, Issue , 2016, Pages 5-9

  Soni, Hitesh ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Co agonist; Diabesity; Glucagon; Glucagon like peptide 1 (GLP 1); Oxyntomodulin

Indexed keywords

ALBIGLUTIDE; ARI 1732TS; DULAGLUTIDE; EFPEGLENATIDE; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYMERA; HM 2525A; IUB 447; LIRAGLUTIDE; LIXISENATIDE; LY 2944876; MEDI 0382; MOD 6030; MOD 6031; OXYNTOMODULIN; PB 1023; SAR 425899; SEMAGLUTIDE; TASPOGLUTIDE; TT 401; TTP 273; UNCLASSIFIED DRUG; VPD 107; VRS 859; ZP 2929; ZYOG 1; 2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PEPTIDE; RECOMBINANT PROTEIN; ROSIGLITAZONE; VENOM;

ARTICLE; DIABETIC OBESITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENERGY EXPENDITURE; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); TREATMENT DURATION; WEIGHT REDUCTION; AGONISTS; ANIMAL; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETIC COMPLICATION; GENETIC TRANSCRIPTION; METABOLISM; MOUSE; MOUSE MUTANT; OBESITY; RAT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MICE; MICE, OBESE; OBESITY; OXYNTOMODULIN; PEPTIDES; RATS; RECOMBINANT PROTEINS; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC; VENOMS;

EID: 84982296136     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2016.08.005     Document Type: Article

References (29)

1. [1] Golay, A., Ybarra, J., Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab 19:4 (2005), 649–663.
2. [2] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:6 (2012), 1364–1379.
3. [3] Center for disease control and prevention (CDC) National Diabetes Fact Sheet, 2014. < http://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf> [accessed 6th May 2016].
4. [4] Chaudhri, O.B., Wynne, K., Bloom, S.R., Can gut hormones control appetite and prevent obesity?. Diabetes Care 31:Suppl. 2 (2008), S284–S289.
5. [5] Kahn, S.E., Haffner, S.M., Heise, M.A., Herman, W.H., Holman, R.R., Jones, N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:23 (2006), 2427–2443.
6. [6] Tharakan, G., Tan, T., Bloom, S., Emerging therapies in the treatment of ‘diabesity’: beyond GLP-1. Trends Pharmacol Sci 32:1 (2011), 8–15.
7. [7] Lefèbvre, P.J., Early milestones in glucagon research. Diabetes Obes Metab 13:Suppl. 1 (2011), 1–4.
8. [8] Day, J.W., Ottaway, N., Patterson, J.T., Gelfanov, V., Smiley, D., Gidda, J., et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:10 (2009), 749–757.
9. [9] Sjölund, K., Sandén, G., Håkanson, R., Sundler, F., Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 85:5 (1983), 1120–1130.
10. [10] Lorenz, M., Evers, A., Wagner, M., Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett 23:14 (2013), 4011–4018.
11. [11] Tomlinson, B., Hu, M., Zhang, Y., Chan, P., Liu, Z.M., An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opin Investig Drugs 25:2 (2016), 145–158.
12. [12] Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373:1 (2015), 11–22.
13. [13] Davies, M.J., Bergenstal, R., Bode, B., Kushner, R.F., Lewin, A., Skjøth, T.V., et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314:7 (2015), 687–699.
14. [14] Henry, R.R., Rosenstock, J., Logan, D., Alessi, T., Luskey, K., Baron, M.A., Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications 28:3 (2014), 393–398.
15. [15] Pocai, A., Unraveling oxyntomodulin, GLP1’s enigmatic brother. J Endocrinol 215:3 (2012), 335–346.
16. [16] Habegger, K.M., Heppner, K.M., Geary, N., Bartness, T.J., DiMarchi, R., Tschöp, M.H., The metabolic actions of glucagon revisited. Nat Rev Endocrinol 6:12 (2010), 689–697.
17. [17] Habegger, K.M., Stemmer, K., Cheng, C., Müller, T.D., Heppner, K.M., Ottaway, N., et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62:5 (2013), 1453–1463.
18. [18] Kosinski, J.R., Hubert, J., Carrington, P.E., Chicchi, G.G., Mu, J., Miller, C., et al. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity (Silver Spring) 20:8 (2012), 1566–1571.
19. [19] Wynne, K., Park, A.J., Small, C.J., Patterson, M., Ellis, S.M., Murphy, K.G., et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54:8 (2005), 2390–2395.
20. [20] Wynne, K., Park, A.J., Small, C.J., Meeran, K., Ghatei, M.A., Frost, G.S., et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 30:12 (2006), 1729–1736.
21. [21] Finan, B., Clemmensen, C., Müller, T.D., Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol 418:Pt. 1 (2015), 42–54.
22. [22] Cegla, J., Troke, R.C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K.A., et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63:11 (2014), 3711–3720.
23. [23] Tan, T.M., Field, B.C., McCullough, K.A., Troke, R.C., Chambers, E.S., Salem, V., et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62:4 (2013), 1131–1138.
24. [24] Day, J.W., Gelfanov, V., Smiley, D., Carrington, P.E., Eiermann, G., Chicchi, G., et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers 98:5 (2012), 443–450.
25. [25] Pocai, A., Carrington, P.E., Adams, J.R., Wright, M., Eiermann, G., Zhu, L., et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58:10 (2009), 2258–2266.
26. [26] Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:24 (2007), 2457–2471.
27. [27] U.S. Food and Drug Administration: Guideline for industry: diabetes mellitus-evaluating cardiovascular risk in a new antidiabetic therapies to treat type 2 diabetes, 2008. Available from < http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf> [accessed 6th May 2016].
28. [28] Bhutta, H.Y., Rajpal, N., White, W., Freudenberg, J.M., Liu, Y., Way, J., et al. Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats. PLos One, 10(3), 2015, e0122273.
29. [29] Soni, H., Euglycemic ketoacidosis and sodium glucose co-transporter 2 inhibitors: is this novel class safe for the diabetic patients?. MOJ Toxicol, 1(4), 2015, 00021.